
All patients^{a} (n = 220)

NDM (n = 151)

DMHNDM (n = 34)

DMHDMH (n = 20)

ANOVA pvalue^{b}

Reference (n = 235)

Ttest pvalue^{c}


mean (SD)

mean (SD)

mean (SD)

mean (SD)

mean (SD)


Age (years)

44.6 (9.5)

42.1 (9.0)

50.5 (8.1)*

51.5 (7.4)*

7 e^{−9}

45.5 (8.9)*

2 e^{−4}

Gender (female/male)

150/70

113/38

18/16

9/11

0.01

120/115

1 e^{−6}

Height (cm)

171.8 (9.6)

171.0 (9.8)

174.5 (8.0)

171.2 (11.4)

0.167

171.0 (9.4)

0.996

Weight (kg)

125.2 (21.6)

126.3 (22.4)

126.4 (20.6)

117.6 (19.7)

0.244

79.2 (15.5)*

1 e^{−61}

BMI (kg/m^{2})

42.3 (5.8)

43.1 (5.9)

41.4 (5.4)

40.0 (3.6)*

0.006

27.0 (4.5)*

1 e^{−81}

Systolic blood pressure (mmHg)

128 (14.7)

126.8 (14.9)

131.2 (12.6)

128.2 (14.7)

0.285

132.1 (19.1)*

0.004

Diastolic blood pressure (mmHg)

82.2 (10.1)

82.0 (11.0)

81.4 (6.8)

82.4 (10.1)

0.93

82.3 (16.7)

0.831

HbA1c (mmol/mol)

39.0 (9.7)

34.5 (3.8)

48.8 (11.7)*

55.2 (10.0)*

4 e^{−12}

40.7 (5.8)*

5 e^{−26}

HbA1c (%)

5.7 (0.89)

5.3 (0.35)

6.6 (1.07)

6.9 (0.91)

ND

5.9 (0.53)

ND

Total cholesterol (mmol/L)

4.74 (1.04)

4.98 (0.96)

4.22 (1.11)*

4.24 (1.17)*

4 e^{−5}

5.54 (1.07)*

5 e^{−7}

HDLCholesterol (mmol/L)

1.15 (0.30)

1.19 (0.29)

1.06 0.36)

1.09 (0.35)

0.038

1.35 (0.32)*

2 e^{−6}

LDLCholesterol (mmol/L)

2.88 (0.95)

3.12 (0.85)

2.36 (0.97)* (n = 32)

2.27 (1.13)* (n = 18)

1 e^{−6}

3.69 0.97) (n = 67)*

2 e^{−5}

VLDLCholesterol (mmol/L)

0.71 (0.32)

0.67 (0.30)

0.75 (0.30) (n = 32)

0.89 (0.47) (n = 18)

0.086

0.58 (0.25) (n = 67)*

0.033

Triglycerides (mmol/L)

1.67 (1.09)

1.50 (0.74)

2.11 (1.95)

2.13 (1.26)

0.038

1.28 (0.83)*

0.008

Statin treatment (+/−)

49/171

12/139

17/17*

13/7*

5 e^{−7}

NA
 
 Data are reported as mean (SD). If the number of patients with available clinical data was less than 95% of the total of patients in the group, the actual number is specified. SD Standard deviation, BMI Body mass index, HbA1c Glycated hemogobin, HDL Highdensity lipoprotein, LDL Lowdensity lipoprotein, VLDL Very lowdensity lipoprotein, NDM Patients without diabetes mellitus (DM), DMHNDM Patients with DM in remission after Rouxeny gastric bypass surgery (RYGB), DMHDMH Patients with DM not in remission after RYGB. Reference, a population of healthy individuals with normal weight. ^{a} All patients also include 15 patients who belong to other subgroups than the three showed in table; ^{b} pvalue from Oneway ANOVA comparing the three patientsubgroup means; ^{c} pvalue from independent samples ttest comparing the reference group mean to the mean in the patient subgroup NDM. ^{*} indicates significant difference (p < 0,05) when compared to the NDM group. No significant differences were found between the two diabetes subgroups. The two diabetes subgroups were not compared to the reference group. Post hoc pvalues from Tukey and GamesHowell are not shown in table. Data on statin treatment were not available (NA) for the reference population